Ignite Creation Date:
2025-12-24 @ 11:45 PM
Ignite Modification Date:
2025-12-25 @ 9:39 PM
Study NCT ID:
NCT04902651
Status:
TERMINATED
Last Update Posted:
2022-07-19
First Post:
2021-05-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
HM242-Gel vs Comparator
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014647', 'term': 'Varicose Ulcer'}], 'ancestors': [{'id': 'D014648', 'term': 'Varicose Veins'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D007871', 'term': 'Leg Ulcer'}, {'id': 'D012883', 'term': 'Skin Ulcer'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 73}}, 'statusModule': {'whyStopped': 'stopped for futility', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2021-05-21', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-05', 'completionDateStruct': {'date': '2022-02-16', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-07-15', 'studyFirstSubmitDate': '2021-05-21', 'studyFirstSubmitQcDate': '2021-05-21', 'lastUpdatePostDateStruct': {'date': '2022-07-19', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-05-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-01-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The primary objective of the study is to demonstrate that the HM242-Gel performs at least comparably to INTRASITE Gel with regard to wound healing.', 'timeFrame': '28 days', 'description': 'The primary variable is defined as the relative reduction of the wound area of a patient in percentage 28 days (4 weeks) after baseline. The wound size area is measured on site by the tracing method.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Venous Leg Ulcer']}, 'descriptionModule': {'briefSummary': 'The primary objective of the study is to demonstrate that the HM242-Gel performs at least comparably to INTRASITE Gel with regard to wound healing.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Males or females of at least 18 years at the time of enrolment\n2. The legal capacity and ability to understand the nature, risks, significance and scope of the clinical trial and to determine his or her will accordingly\n3. Signed form of consent, including the understanding of and willingness by the patient to participate in the clinical study and ability to comply with study procedures and study visit schedule\n4. Patients must be willing to have all dressing changes performed by the wound specialist, with no treatments at home\n5. Presence of at least one venous ulcer of the lower leg extending through the full thickness of the skin but not down to muscle, tendon or bone\n6. Size of study ulcer ≥ 2cm² and ≤ 100cm² measured using the tracing method.\n7. Presence of venous leg ulcer for at least 6 weeks, but not longer than 12 months\n8. Ankle Brachial Pressure Index (ABI) \\> 0.75\n9. In the case of a female patient of childbearing potential, willingness to use highly effective methods of contraception (failure rate of \\< 1% when used consistently and correctly);acceptable contraceptive measures in this trial are: combined pill and progestin-only pill, contraceptive patch, ring or injection, Etonogestrel implant, intrauterine device (IUD) (copper and Levonogestrel), male sterilization (vasectomy), female sterilization (abdominal, laparoscopic, hysteroscopic), or sexual abstinence.\n\nExclusion Criteria:\n\n1. Patients kept in an institution due to an official or court order\n2. Patients dependent on the Sponsor, Investigator or Site\n3. Patients suspected of having SARS-CoV-2 infection or COVID-19 disease\n4. Study ulcer judged by the Investigator to be caused by a medical condition other than venous insufficiency\n5. Study ulcer with signs and symptoms of infection, or under suspicion of cancer\n6. Study ulcer under treatment with topical antimicrobials within past two weeks or systemic antimicrobial treatment within past two weeks\n7. In the case of heavily exuding ulcers, if in the opinion of Investigator the patient is not suitable for treatment with gel\n8. More than two venous leg ulcers or more than two chronic wounds\n9. Dementia stage greater than 3 according to Reisberg\n10. Known allergies against wound dressings used in the study\n11. Known chronical skin diseases, dermatoses, or known allergies or other conditions which might trigger dermatitis\n12. Acute cases of substance use disorders (ICD-10 F1x.1 or F1x.2)\n13. Buerger's disease\n14. Participation in Medical Device trials less than 4 weeks ago or participation in Drug trials less than six months ago\n15. Terminally ill patients\n16. Patients with poorly managed diabetes mellitus: absence of a glycated hemoglobin test within the last 3 months or a result of HbA1c ≥ 8% not older than 3 months, or a major diabetes-related incident within the past 4 weeks\n17. Ulcers of diabetic origin\n18. Patients under treatment with systemic corticosteroids, immunosuppressant, cytotoxic chemotherapy, or radiotherapy\n19. Presence of one or more medical conditions (other than venous insufficiency and diabetes) as determined by medical history, which:\n\n * Is known to interfere with the wound healing process (e.g. arteriopathy, vasculitis, rheumatoid arthritis, systemic lupus erythematosus, other auto-immune diseases, cancer, immunodeficiency, severe lymphedema of the leg, thrombophilia)\n * In the opinion of the Investigator, would make the patient an inappropriate candidate for this venous ulcer healing study (e.g. malnutrition, hygiene, obesity)\n20. Pregnant or lactating patients"}, 'identificationModule': {'nctId': 'NCT04902651', 'briefTitle': 'HM242-Gel vs Comparator', 'organization': {'class': 'INDUSTRY', 'fullName': 'B. Braun Ltd. Centre of Excellence Infection Control'}, 'officialTitle': 'A PROSPECTIVE, CONTROLLED, RANDOMIZED, OPEN-LABEL PREMARKET MULTICENTER STUDY OF THE PERFORMANCE OF THE HM242-GEL VS COMPARATOR IN PATIENTS UNDER THE CONDITION OF VENOUS LEG ULCER', 'orgStudyIdInfo': {'id': 'OPM-G-H-2004'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'HM242-Gel', 'interventionNames': ['Device: HM242-Gel']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Intrasite Gel', 'interventionNames': ['Device: Intrasite Gel']}], 'interventions': [{'name': 'HM242-Gel', 'type': 'DEVICE', 'description': 'HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer', 'armGroupLabels': ['HM242-Gel']}, {'name': 'Intrasite Gel', 'type': 'DEVICE', 'description': 'HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer', 'armGroupLabels': ['Intrasite Gel']}]}, 'contactsLocationsModule': {'locations': [{'zip': '16000', 'city': 'Prague', 'state': 'Praha 6', 'country': 'Czechia', 'facility': 'Kožní ambulance Fialová, s.r.o.', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '018 52', 'city': 'Pruské', 'country': 'Slovakia', 'facility': 'Viliam Cibik', 'geoPoint': {'lat': 49.02636, 'lon': 18.21257}}, {'zip': '911 01', 'city': 'Trenčín', 'country': 'Slovakia', 'facility': 'Rudolf Suchy', 'geoPoint': {'lat': 48.89452, 'lon': 18.04436}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'B. Braun Ltd. Centre of Excellence Infection Control', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}